Ardelyx on X: "Press Release: FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor) Read more here: https://t.co/drMd3jYvKl https://t.co/DYmGNsa9Nt" / X
Ardelyx, Inc. (NASDAQ:ARDX) Q3 2023 Earnings Call Transcript
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Ardelyx, Inc. (ARDX) Investigation
ARDX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 28, 2021 in the Class Action Filed on Behalf of Ardelyx, Inc. Limited Shareholders
Ardelyx Inc Stock News | ARDX Company Stock News and Press Releases | FinancialContent Business Page
Ardelyx
Ardelyx, Inc. (ARDX) Stock Price, Quote & News - Stock Analysis
Positive FDA AdCom votes for Ardelyx's tenapanor
ARDELYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ardelyx, Inc. on Behalf of Ardelyx Stockholders and Encourages Investors to Contact the Firm | Business Wire
Ardelyx Prepares for Battle with FDA Over Rejected CKD Drug | BioSpace
Ardelyx, Inc. on LinkedIn: Press Release: Ardelyx Announces Poster Presentations on XPHOZAH®…
Ardelyx, Inc. (ARDX) Stock Price, Quote & News - Stock Analysis
Ardelyx Inc Stock News | ARDX Company Stock News and Press Releases | FinancialContent Business Page
Ardelyx (@ardelyx) / X
And we Have Another Triple! Ardelyx (ARDX) Touches $5.00, up 333%. | Internet | Biotech Stock Review
Ardelyx Announces Publication of 52-Week Phase 3 PHREEDOM Trial | PDF | Chronic Kidney Disease | Therapy
Ardelyx
FY2023 Earnings Forecast for Ardelyx, Inc. (NASDAQ:ARDX) Issued By Cantor Fitzgerald - MarketBeat
Ardelyx Grants Stock Options & RSUs to New Employees
Ardelyx wins FDA approval for phosphate absorption inhibitor - Pharmaceutical Technology
News & Events | Ardelyx, Inc.
Ardelyx: Q3 Earnings Snapshot -October 31, 2023 at 07:30 am EDT | MarketScreener
Ardelyx Announces Proposed Public Offering of Common Stock
Adding Ardelyx (ARDX) $1.57 to Watch List. | Internet | Biotech Stock Review
Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan
